The Effect of a Biomechanical Footwear as a Non-invasive Alternative to Total Knee Replacement and as an Additional Rehabilitation Regimen Postoperatively

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Osteoarthritis (OA), the most common type of arthritis, affects more than 32.5 million adults in the United States. It is also among the most expensive condition to treat when joint replacement surgery is required. Although biomechanics plays an important role in OA disease, the non-surgical treatment options addressing biomechanics are scarce with limited effect. AposHealth is the fist biomechanical treatment that was shown to have a significant short-term effect on patients with knee OA. The main objectives of this study are: 1. To assess AposHealth, a non-invasive home-based biomechanical treatment, as an alternative treatment for patients who are eligible for Total Knee Replacement (TKR). 2. To assess AposHealth as a new post-operative rehabilitation tool for patients post TKR.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Maximum Age: 80
Healthy Volunteers: f
View:

• Men or non-pregnant women

• Between ages 45 and 80, inclusive

• ACR clinical criteria for OA of the knee

• Symptomatic uni- or bilateral OA of the knee for at least six months

• Radiological criteria: X-rays showing tibiofemoral knee osteoarthritis defined as at least Kellgren and Lawrence Grade 2

• At least a moderate NPRS pain score at baseline (≥5)

• Score of 1-3 based on the American Society of Anesthesiologists Physical Status Classification System

• Willing and able to read, comprehend, and sign the study informed consent form in English prior to study specific procedure

Locations
United States
Pennsylvania
Geisinger Medical Center
RECRUITING
Danville
Geisinger - Orthopaedics Wilkes-Barre
RECRUITING
Wilkes-barre
Contact Information
Primary
Michael Suk, MD
orthoresearch@geisinger.edu
570-271-6541
Backup
Kenneth Sams
kbsams@geisinger.edu
570-214-4806
Time Frame
Start Date: 2021-07-22
Estimated Completion Date: 2026-03
Participants
Target number of participants: 150
Treatments
Experimental: AposHealth
Following the initial consultation and calibration of the Apos device in the clinic, the patients will receive from his therapist a home-based treatment plan. This usually includes wearing the device for about 20 minutes with about 20% of weight-bearing (patient is instructed to wear the Apos and just be with the device and go about his/her daily routine). A gradual increase in usage time is prescribed reaching up to 60 min wear time with about 40% weight-bearing.~Patients are requested to return to follow-up (FU) appointments after 1, 3, 6, 9 and 12 months. In addition, patients will have a remote FU after 1-week to confirm they use AposHealth as advised. During the follow-up appointment, re-assessment of clinical outcomes and gait patterns are performed and the calibration of the Apos device is adjusted as needed. The treatment plan is adjusted, and patients are encouraged to continue to wear the device regularly at home.
Active_comparator: Total Knee Replacement (TKR)
Patients will undergo TKR according to Geisinger's policy, guidelines and care protocol.~The study baseline visit will occur 6 weeks postoperative for TKR groups.
Experimental: Post TKR traditional physical therapy (PT) and AposHealth
Patients who have had a knee replacement and were assigned to the traditional PT+ AposHealth group will follow Geisinger post-operative rehab protocol and will also receive AposHealth and follow the rehabilitation protocol.~AposHealth will start six weeks post-op and will continue for 12 months. Patients will receive AposHealth similar to the non-invasive group, i.e., will have an initial evaluation (IE) and calibration of the Apos device, have a remote FU after one week from IE and in-clinic FUs at 1, 3 6, 9 and 12 months.
Sponsors
Leads: Geisinger Clinic
Collaborators: Apos Medical and Sports Technology Ltd.

This content was sourced from clinicaltrials.gov